A Matter of Life and Death
July 26, 2012 | Story
Ramanan Laxminarayan provides an economic analysis on the problem of antibiotic resistance that have contributed to rising resistance rates.
You are now viewing 1 - 10 of 57 results
July 26, 2012 | Story
Ramanan Laxminarayan provides an economic analysis on the problem of antibiotic resistance that have contributed to rising resistance rates.
October 1, 2011 | Journal Article
This study suggests that government incentives are needed to encourage the research and development that goes into producing novel antibiotics, in addition to increasing development of new ones.
November 14, 2011 | Journal Article
Index developed to quantify changes in drug resistance over time.
November 1, 2006 | Journal Article
Since the 1960s, scientists and pharmaceutical representatives have called for the advancement and development of new antimicrobial drugs to combat infectious diseases. In January 2005, Senate Majority Leader Bill Frist (R-TN), M.D., introduced a bi ...
March 1, 2009 | Issue Brief
This policy brief from RWJF grantee Extending the Cure looks at the obstacles around developing a staph vaccine.
August 1, 2010 | Issue Brief
This policy brief from RWJF grantee Extending the Cure examines phages the advantages and disadvantages of phage therapy, other potential applications and the road ahead
July 30, 2012 | Pioneering Ideas Blog Post
Brian Quinn weighs in on Extending the Cure Project Director Ramanan Laxminarayan’s suggestion that we view antibiotics effectiveness as a natural resource.
August 21, 2012 | Pioneering Ideas Blog Post
Extending the Cure Director Ramanan Laxminarayan examines the dangers of antibiotic overuse.
December 19, 2011 | Pioneering Ideas Blog Post
Now that flu season is upon us, more and more Americans will be tweeting about aches and pains and other symptoms that could signal the onset of the flu.
February 22, 1010 | Journal Article
A new study finds the clinical and economic costs of sepsis and pneumonia infections contracted while in the hospital are substantial and vary among patient groups.